Pharmacogenomics market size is estimated to reach US$ 8.87 Billion by 2033, North America leads the market with 44.2% market share | Major Players & Tech Partnerships.

The global pharmacogenomics market was valued at US$ 3.59 Billion in 2023. The market size reached US$ 3.92 Billion in 2024 and is expected to reach US$ 8.87 Billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.

Pharmacogenomics Market Growth is driven by rising demand for personalized medicine, genetic testing advancements, increasing chronic disease prevalence, and the need for safer, more effective drugs tailored to individual genetic profiles.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/pharmacogenomics-market?prtk

United States: Key Industry Developments
✅ January 2026: Illumina launched TruSight Oncology 500 PGx panel with FDA breakthrough designation, enabling comprehensive genotyping for 150+ cancer drugs across 2,000 U.S. community hospitals.​
Reduces ADR rates 45% through real-time CYP2D6/VEGFR variant detection during active chemotherapy regimens.

✅ December 2025: OneOme integrated RightMed PGx platform with Epic EHR at Mayo Clinic, serving 500K patients with preemptive genotyping that cuts opioid switching 60% in post-surgical pain management.

✅ November 2025: Tempus launched xT CDx companion diagnostic covering 50 pharmacogenomic biomarkers, accelerating FDA approvals for precision oncology across 1,500 network practices nationwide.

Asia Pacific / Japan: Key Industry Developments
✅ January 2026: Riken Genesis received PMDA approval for PGx-1000 panel targeting 200 Japanese-approved drugs, standardizing genotyping for 3M cardiovascular patients through national health insurance coverage.

✅ December 2025: Takara Bio launched CLP-1000 next-gen sequencer with integrated PGx workflow, processing 10K samples monthly across Tokyo University Hospital network for TB medication optimization.

✅ October 2025: Sysmex Asia Pacific deployed Genetra PGx platform at 500 clinics, achieving 92% warfarin dose accuracy through VKORC1/CYP2C9 testing for 1.2M atrial fibrillation patients nationwide.

pharmacogenomics Market Recent M&A activities:-

→ In August 2025, PGxAI and Sequencing.com formed a strategic partnership to advance affordable pharmacogenomics reporting at scale PGxAI will deliver pharmacogenomic reports via Sequencing.com, expanding consumer‐accessible gene‐guided prescribing support.

→ On March 19, 2025, InformedDNA acquired Coriell Life Sciences a precision health company specializing in pharmacogenomic services and clinical decision support to expand its genomic insights platform.

→ On February 3, 2025, Tempus AI completed the acquisition of Ambry Genetics a leader in genetic testing and pharmacogenomic insights in a transaction worth approximately $600 million (with $375 million cash and $225 million in stock, including a $100 million lock‐up component).

pharmacogenomics Market key Players:-
Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories Inc., Illumina, Eurofins Scientific, Pacific Biosciences of California Inc., Qiagen, and Thermo Fisher Scientific Inc., among others.

Top 5 Key Players Analysis:-

1. Thermo Fisher Scientific Inc. - Market Leader (17 share)
Thermo Fisher leads the global pharmacogenomics market with a broad portfolio of sequencing, PCR assays, and reagents that support personalized medicine. Its extensive product range and global clinical reach solidify its dominant position.

2. Illumina, Inc. - Second largest (16 share)
Illumina is a leader in high‐throughput sequencing technologies essential for pharmacogenomics studies, widely used in both research and clinical settings. Its innovation in sequencing platforms and strategic partnerships continue to drive market growth.

3. QIAGEN N.V. - Top contender (10% share)
QIAGEN provides molecular diagnostics, genotyping kits, and bioinformatics tools that enable genotype‐guided treatment decisions. Its scalable solutions and collaborations with pharma customers strengthen its role in clinical pharmacogenomics.

4. Agilent Technologies, Inc. - Key player (8% share)
Agilent supplies analytical instruments, microarray and PCR technologies that support genetic analysis in pharmacogenomics research and diagnostics. Its advanced platforms and reagent offerings help laboratories profile genetic variants.

5. Bio‐Rad Laboratories, Inc. - Important contributor (7.5% share)
Bio‐Rad develops tools and reagents for life science research and clinical diagnostics, facilitating detailed genetic assessments used in pharmacogenomic applications. Its products enable precise genetic analysis that aids personalized therapy development.

pharmacogenomics Market Top Technological Partnerships (2026 & 2025):-

✅ October 2025: PGxAI partnered with Sequencing.com to integrate AI-powered pharmacogenomic reports into consumer genetic platforms, targeting $150B ADR cost reduction through CYP2D6/CYP2C9 insights for 10M users.
​Compatible with 23andMe/Ancestry data formats, enabling real-time prescribing optimization via app-based delivery.

✅ August 2025: QIAGEN collaborated with Helix on companion diagnostics for genetic diseases, combining NGS workflows with population-scale biobanks to accelerate PGx panel approvals across 200+ medications.
Focuses on rare variant detection in oncology/cardiology, cutting clinical trial timelines by 25% through preemptive genotyping.

✅ May 2025: Oxford Nanopore Technologies teamed with Twist Bioscience on a Pharmacogenomics Beta Program, merging long-read nanopore sequencing with synthetic DNA libraries for 98% SNP accuracy in drug metabolism panels.
​Enhances personalized antidepressant/warfarin dosing for 5M patients, with portable sequencer deployment in community clinics.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=pharmacogenomics-market?prtk

pharmacogenomics Market Market Drivers :-

• The shift from one‐size‐fits‐all to individualized therapies is central with over 65% of healthcare systems integrating pharmacogenomic testing to optimize drug responses and cut trial‐and‐error prescribing. This trend directly fuels market adoption as clinicians seek tailored treatment paths.

• As conditions like cancer, cardiovascular disease, and diabetes become more prevalent, clinicians increasingly rely on genetic insights to select effective therapies. Pharmacogenomics helps predict drug responses and reduce adverse events a clear growth engine for the industry.

• Ongoing technological progress in next‐generation sequencing (NGS), PCR, and AI‐enabled analysis is enhancing diagnostic accuracy and lowering turnaround times with new platforms improving research efficiency by 25-35%. This accelerates adoption across clinical and research settings.

• More than 60% of patients now benefit from gene‐guided prescriptions, and a large majority of hospitals are adopting genomic‐based treatment plans, especially in oncology and chronic care specialties. This increases routine utilization of pharmacogenomic testing.

• Global funding for genomic research jumped 30% in recent years, while venture funding in personalized medicine startups grew 40%, indicating strong investor confidence and resource flows into pharmacogenomics innovation.

• Educational initiatives and clinical training programs are expanding with roughly 31% of physicians now using genetic data for dosing decisions, while 60%+ of patients prefer gene‐informed treatments. This cultural shift directly supports demand.

Pharmacogenomics Market Regional Insights:-

1) North America
North America is the largest pharmacogenomics market, commanding the highest global share at around 44.2%, driven by strong clinical adoption of genetic testing and supportive reimbursement policies in the U.S. and Canada. The region's advanced healthcare infrastructure and biotech presence continuously reinforce its dominance.

2) Europe
Europe holds the second‐largest share at approximately 29.3%, led by Germany, the UK, and France with growing integration of pharmacogenomics into routine care and strong regulatory frameworks. Continued EU funding and cross‐border research initiatives support steady regional growth.

3) Asia Pacific
Asia Pacific accounts for an estimated 22.4% of the market, with rapid growth due to government genomic initiatives, expanding healthcare infrastructure and increasing testing adoption in China, Japan, India, and Australia. The region is forecast to be one of the fastest‐growing segments.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/pharmacogenomics-market?prtk

Pharmacogenomics Market Market Segmentation

By Product & Service Type:
Kits & Reagents, Instruments, Software & Services - essential tools for testing and analysis in pharmacogenomics.

By Technology:
DNA Sequencing, PCR, Microarray, Electrophoresis, Mass Spectrometry, Others - techniques used for genetic profiling and biomarker identification.

By Application:
Drug Discovery, Personalized Medicine, Clinical Research, Others - key areas where pharmacogenomics guides therapy and research.

By Disease Area:
Oncology, Cardiovascular, Neurological, Infectious, Mental Health, Others - genetic insights applied across multiple diseases for better treatment outcomes.

This research report delivers actionable insights, data-driven analysis, and future-ready perspectives that enable informed decision-making, reduce market risks, and uncover growth opportunities across the industry

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.